Status:
UNKNOWN
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
Lead Sponsor:
Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions:
Lung Cancer
Lung Cancer Stage III
Eligibility:
All Genders
18-80 years
Brief Summary
The introduction of maintenance immunotherapy with the anti PD-L1 inhibitor durvalumab opened a new therapeutic window for stage III NSCLC patients who achieve at least stable disease after chemo-radi...
Detailed Description
Specific aim (one): To collect and analyze CT scans at diagnosis and after chemoradiation, and assign them to a specific radiomic signature (blind assessment). Specific aim (two): \- To correlate t...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
- Age 18-80
- Stage IIIA-IIIB-IIIC disease judged to be unresectable by a multidisciplinary team including pulmonologists, thoracic surgeons, medical and radiation oncologists.
- Signed informed consent
Exclusion
- Inability to sign the informed consent
- Absence of analyzed CT images
Key Trial Info
Start Date :
January 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04364776
Start Date
January 15 2020
End Date
December 15 2024
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy, 27100